Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): clinical, technical and socio-economic considerations.Biol Blood Marrow Transplant.(2019).
Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.Bone Marrow Transplant.(2016).
Autologous transplant remains the preferred therapy for relapsed APL in CR2.Bone Marrow Transplant.(2016).
Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT.Bone Marrow Transplant.(2016).
Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.Bone Marrow Transplant.(2016).
Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.Bone Marrow Transplant.(2015).
Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT.Bone Marrow Transplant.(2015).
Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.Bone Marrow Transplant.(2015).
Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.Bone Marrow Transplant.(2015).
Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.Bone Marrow Transplant.(2015).
Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.Bone Marrow Transplant.(2015).
90Y-ibritumomab tiuxetan, fludarabine, busulfan and anti-thymocyte globulin reduced intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.Ann Oncol.(2014).